| Placebo group (n = 10) | Low dose group (n = 10) | High dose group (n = 10) | P-value |
---|---|---|---|---|
PAI-1 [mean (SD); ng/mL] | Â | Â | Â | 0.032 |
 T1 | 23.7 ± 2.5 | 22.9 ± 2.5 | 24.1 ± 2.2 |  |
 T2 | 28.2 ± 1.9 | 27.6 ± 2.8 | 28.4 ± 1.9 |  |
 T3 | 56 ± 5 | 50 ± 7a | 57 ± 6 |  |
 T4 | 52 ± 6 | 45 ± 8a | 51 ± 6 |  |
 T5 | 43.0 ± 2.2 | 39.6 ± 7.9 | 43.2 ± 4.5 |  |
TAFI [mean (SD); ng/mL] | Â | Â | Â | 0.046 |
 T1 | 17.5 ± 1.6 | 18.1 ± 1.1 | 16.4 ± 0.7 |  |
 T2 | 20.9 ± 1.7 | 21.8 ± 2.0 | 21.5 ± 1.6 |  |
 T3 | 43.0 ± 2.9 | 37.1 ± 4.4a | 40.5 ± 5.2 |  |
 T4 | 37 ± 5 | 32 ± 6a | 37 ± 5 |  |
 T5 | 33.5 ± 2.2 | 29.4 ± 4.1a | 32.5 ± 3.6 |  |
PAP [mean (SD); ng/mL] | Â | Â | Â | 0.176 |
 T1 | 13.9 ± 1.9 | 15.8 ± 1.5 | 13.3 ± 2.1 |  |
 T2 | 19.7 ± 2.4 | 20.2 ± 2.3 | 19.7 ± 2.5 |  |
 T3 | 42 ± 4 | 39 ± 6 | 45 ± 8 |  |
 T4 | 37 ± 7 | 34 ± 7 | 39 ± 6 |  |
 T5 | 31 ± 6 | 28 ± 3 | 33 ± 5 |  |
tPA [mean (SD); ng/mL] | Â | Â | Â | 0.113 |
 T1 | 3.0 ± 0.3 | 3.5 ± 0.4 | 3.3 ± 0.6 |  |
 T2 | 3.67 ± 0.37 | 4.24 ± 0.55 | 4.17 ± 0.24 |  |
 T3 | 7.9 ± 1.2 | 7.5 ± 1.6 | 8.3 ± 1.1 |  |
 T4 | 6.6 ± 1.1 | 6.3 ± 1.0 | 7.2 ± 1.1 |  |
 T5 | 5.7 ± 1.1 | 5.6 ± 0.7 | 6.3 ± 0.9 |  |
TM [mean (SD); ng/mL] | Â | Â | Â | 0.019 |
 T1 | 1.33 ± 0.09 | 1.55 ± 0.15 | 1.57 ± 0.14 |  |
 T2 | 1.69 ± 0.16 | 1.65 ± 0.15 | 1.72 ± 0.18 |  |
 T3 | 3.5 ± 0.5 | 3.2 ± 0.5 | 3.7 ± 0.6 |  |
 T4 | 2.9 ± 0.4 | 2.6 ± 0.5 | 3.3 ± 0.7b |  |
 T5 | 2.66 ± 0.48 | 2.24 ± 0.32 | 2.57 ± 0.28 |  |